THCV

Δ9-tetrahydrocannabivarin

6Node page

what any key link opens

psx:substance/thcv/claim/813c9327-fee9-475d-971b-928e1b28c5a6

claim2026-05-11workinginconclusive

derived from · upstream

usedPhytocannabinoids: Origins and Biosynthesispsx:substance/thcv/src/doi:10.1016/j.tplants.2020.05.005

feeds · downstream

informed_bysection/chemistry.full@1psx:substance/thcv/section/chemistry.full@1

psx:substance/thcv/claim/813c9327-fee9-475d-971b-928e1b28c5a6
├─ used  src/doi:10.1016/j.tplants.2020.05.005  Phytocannabinoids: Origins and Biosynthesis
  ├─ informed_by  claim/5e0ce23f-2549-43bd-acf1-0169038979f1  Claim in chemistry — inconclusive  working
  ├─ informed_by  claim/2c3762e4-3d0d-4bab-88e5-e3254c4d00e8  Claim in chemistry — inconclusive  working
  ├─ informed_by  claim/f0f0d769-04f7-4dc5-a906-61365bfea5fb  Claim in chemistry — supported
    ├─ used  src/doi:10.1038/sj.bjp.0707442  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin
    ├─ used  src/url:fdd51976cdf438b4  Tetrahydrocannabivarin — Wikipedia
    ├─ used  src/pmid:16205722  Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist
    ├─ used  src/doi:10.2337/dc16-0650  Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study
    ├─ used  src/doi:10.1111/bph.13000  The phytocannabinoid, Δ9-tetrahydrocannabivarin, can act through 5-HT1A receptors to produce antipsychotic effects
    ├─ used  src/doi:10.1111/bph.12944  Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
    ├─ used  src/pmid:17245367  The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo
    ├─ used  src/doi:10.26828/cannabis/2024/000206  Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips
    ├─ used  src/doi:10.1186/s42238-021-00062-4  The biosynthesis of the cannabinoids
    ├─ used  src/doi:10.3389/fpls.2016.00019  Cannabis sativa: The Plant of the Thousand and One Molecules
    ├─ used  src/pmid:93147  THCV (Tetrahydrocannabivarin) — PubChem CID 93147
    ├─ used  src/doi:10.3934/Neuroscience.2025003
    ├─ used  src/doi:10.3389/fpls.2018.01969  The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No Strain, No Gain
    ├─ used  src/doi:10.1038/bjp.2008.190  Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes
    ├─ used  src/doi:10.1093/ijnp/pyv092  The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers
    ├─ used  src/doi:10.1016/j.phrs.2016.07.045  Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages
    ├─ used  src/doi:10.1111/j.1476-5381.2010.00756.x  The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice
    ├─ used  src/doi:10.1111/j.1476-5381.2010.01166.x  Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
    ├─ used  src/doi:10.1126/sciadv.adn2453  TRPV3 activation by different agonists accompanied by lipid dissociation from the vanilloid site
    ├─ used  src/doi:10.3389/fphar.2021.777804  Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses
    ├─ used  src/doi:10.3390/ijms23105430  Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes
    ├─ used  src/doi:10.1016/j.phrs.2021.105970  Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors
    ├─ used  src/url:5a17861a26994f43  Pharmacokinetics of Oral Cannabinoid Δ8-Tetrahydrocannabivarin and Its Main Metabolites in Healthy Participants
    ├─ used  src/doi:10.1111/j.1476-5381.2011.01410.x  Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors
    ├─ used  src/doi:10.3390/ijms24032721  Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway
    ├─ used  src/doi:10.4103/ijt.ijt_34_22  Hair Regrowth with Novel Hemp Extract: A Case Series
    ├─ used  src/doi:10.1111/j.1528-1167.2010.02523.x  Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats
    ├─ used  src/doi:10.1016/j.nbd.2020.104892  Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson’s disease
    ├─ used  src/doi:10.1111/bph.15185  A systematic review of minor phytocannabinoids with promising neuroprotective potential.
    ├─ used  src/pmid:19378378  Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice
    ├─ used  src/url:f455de69bfa40eb6  THCV Legal Status by Country 2025: Canada, EU, Australia
    ├─ derived_from  gen/ef7b6257-99e3-4225-8010-33274e23be18  Generation — pipeline-v5
    ├─ generated_by  pub/afae88d3-595c-4917-81b6-039bec009d21  Publication — backfill
      ├─ used  search/401122ca-c808-43ad-9801-7df0dbfc56ca  Searched PubChem for "THCV"
      ├─ used  search/4120b6d1-0aea-4fc9-b5a2-c9246dcc8cdd  Searched PubMed for "THCV tetrahydrocannabivarin pharmacology receptor binding"
      ├─ used  search/91f0069f-88d4-40c6-9f3f-6f9b4f60e1b5  Searched OpenAlex for "tetrahydrocannabivarin THCV cannabinoid receptor"
      ├─ used  search/f0eacdbc-6d4b-46a7-ae09-a13194630ae5  Searched PubMed for "THCV tetrahydrocannabivarin GWP42004 type 2 diabetes clinical trial"
      ├─ used  search/6777ba4d-0224-43fd-836f-7d52c41f12c7  Searched PubMed for "tetrahydrocannabivarin neuroprotection Parkinson's disease"
      ├─ used  search/1a26a327-4328-4407-9a48-bf6d4db08efe  Searched ClinicalTrials.gov for "tetrahydrocannabivarin THCV"
      ├─ used  search/7ba8799a-4e40-4c6a-83f4-cf49bb88209d  Searched PubMed for "THCV tetrahydrocannabivarin obesity appetite diabetes metabolic"
      ├─ used  search/47e3be6a-e137-43f2-b65a-12ea0c3a9647  Searched PubMed for "tetrahydrocannabivarin THCV insulin sensitivity mouse model obesity ameliorates glucose"
      ├─ used  search/d564674f-6382-43ca-ac7d-dedd2c08f732  Searched PubMed for "THCV default mode network fMRI resting state functional connectivity brain imaging"
      ├─ used  search/a08f7556-5a35-4aa5-8308-fc5298d73ff1  Searched WebSearch for "THCV first isolation discovery 1970 Gill Jones cannabis history"
      ├─ used  search/62233f87-ebc4-48a6-b637-d86f57404873  Searched WebSearch for "THCV tetrahydrocannabivarin DEA scheduling legal status USA UK controlled substance"
      ├─ used  search/f19e9c2f-44c0-4bc8-805d-6c909ba862ef  Searched WebSearch for "THCV pharmacokinetics oral dose humans half-life Cmax tmax"
      └─ used  search/1fea62b5-69e5-438e-8d9a-4d4765ba5849  Searched Crossref/DOI verification for "Verify DOIs for key THCV papers"
├─ informed_by  section/chemistry.full@1
  ├─ used  version/1  Revision 1
  ├─ used  claim/c2f1f7dd-7fc8-42ce-bc3f-3e57b8b6e402  Claim in history — inconclusive  working
    ├─ derived_from  issue/notice@6cc1eca3752c  Issued notice
    ├─ derived_from  issue/info_card@cbcce4ed045d  Issued info_card
    ├─ derived_from  issue/emergency@207cf682e28a  Issued emergency
    ├─ derived_from  issue/info_card@4089953e287c  Issued info_card
    ├─ derived_from  issue/emergency@7386375eac13  Issued emergency
    ├─ informed_by  section/history.full@1
      ├─ used  claim/94c5beb0-0a1e-44e6-a6df-3a645de0b61f  Claim in summary — supported
      ├─ used  claim/013b273f-c53c-4355-8feb-7297c0ae8773  Claim in pharmacology — supported
      ├─ used  claim/0f27a429-169b-451d-9fa4-fc668168cb8f  Claim in pharmacology — supported
      ├─ used  claim/e7c9674c-299f-4ea1-bc73-d6ffedaf99d7  Claim in pharmacology — supported
      ├─ used  claim/6700b865-148a-496f-ba61-e8296eb837d1  Claim in comparative-pharmacology — supported
      ├─ used  claim/e8f88724-ab65-4bff-a5e7-1209493470a9  Claim in summary — inconclusive  working
      ├─ used  claim/5d6db983-28ee-4a6e-b0e9-ff9c122253c7  Claim in summary — inconclusive  working
      ├─ used  claim/26f0fa15-196c-445e-92bb-5d301d8f9601  Claim in pharmacology — inconclusive  working
      ├─ used  claim/b09df1ee-444a-42a7-bd1a-b6a660bb5a76  Claim in safety — inconclusive  working
      ├─ used  claim/ed7b4163-02ed-49f7-b042-ab3237cc7ed4  Claim in history — inconclusive  working
      ├─ used  claim/a978f3b7-5590-4103-bb4e-0ddd6215a511  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/bebbd07e-96b1-40dc-a03b-f9d06eff63a0  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/34f6345c-c3d1-44f0-a34a-3c5699c8dbee  Claim in safety — inconclusive  working
      ├─ used  claim/6095c9ad-8902-41b1-8870-b19bf3b1f283  Claim in summary — inconclusive  working
      ├─ used  claim/4a4b06cb-9d1b-4046-a742-819cea14c2af  Claim in summary — inconclusive  working
      ├─ used  claim/74bd91c9-acd2-4c8e-a563-feb559946123  Claim in pharmacology — inconclusive  working
      ├─ used  claim/21663e77-f96b-4851-8daa-7a1382594923  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/59d8788b-9b68-4724-8b06-577298b5f6c7  Claim in safety — inconclusive  working
      ├─ used  claim/4e2b8aed-8651-4486-b1bb-065be6384f49  Claim in safety — inconclusive  working
      ├─ used  claim/355ff503-7919-47b4-bcfb-3120c13e9fb7  Claim in safety — inconclusive  working
      ├─ used  claim/cc9ae7ab-bca0-4a68-a89c-a54a9e03f30c  Claim in history — inconclusive  working
      ├─ used  claim/76e517cc-f1a2-4f96-a846-bf30d5440786  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/f9dca307-668a-443f-9cc3-48981f703aa6  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/d2a8eeaf-cd02-49ab-86bc-c836022fe91a  Claim in pharmacology — inconclusive  working
      ├─ used  claim/fe99cedd-af8e-4892-9f9c-c6c3911faf23  Claim in summary — inconclusive  working
      ├─ used  claim/fc89a15f-1c91-4606-bf48-c8e5b1dbac7c  Claim in safety — inconclusive  working
      ├─ used  claim/86f28531-2ecc-4c79-b91c-cdb8d3e39853  Claim in safety — inconclusive  working
      ├─ used  claim/e6d923d7-2d1a-4759-8a4a-69c1a614ac9a  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/00d54c3a-3dba-4210-a7d5-cb075ad59004  Claim in summary — supported
      ├─ used  claim/4f7370be-9c52-401d-b10e-a340c519667b  Claim in pharmacology — supported
      ├─ used  claim/9ecc16ea-08f9-466e-9dd8-6fc6d2254973  Claim in pharmacology — supported
      ├─ used  claim/71591229-a0f9-4451-aff1-0e9634210c41  Claim in safety — supported
      ├─ used  claim/d50313d3-69a1-4f49-b5bc-8f479202eaae  Claim in safety — supported
      ├─ used  claim/250b07de-959d-4f81-8a9a-b68ab9cd6272  Claim in receptor-pharmacology — supported
      ├─ used  claim/83f0182e-32f7-4e3c-85ee-9f56d95d4332  Claim in neuroscience — supported
      ├─ used  claim/0a0c3709-8923-44fe-bb62-eb70e5120e50  Claim in effects-overview — supported
      ├─ used  claim/ef3dbadc-7056-44a2-91ab-edbb31d6ab25  Claim in pharmacology — inconclusive  working
      ├─ used  claim/b2d04a31-1480-43c8-a942-e85788c78d85  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/2fec1fe3-e834-4111-9de8-62de9ec6a01f  Claim in neuroscience — inconclusive  working
      ├─ used  claim/76ddd72d-78e1-422c-9c33-ad9116b13459  Claim in safety — inconclusive  working
      ├─ used  claim/c2da3e40-e98c-4806-8411-2ca9dcd88fdb  Claim in history — inconclusive  working
      ├─ used  claim/5d1a12d1-f87a-4ae6-a096-fd0da3a1e67b  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/3d24e98e-9f37-4f5b-8a60-28b962dc3a03  Claim in safety — inconclusive  working
      ├─ used  claim/cf5ca979-d427-4354-b0d0-c5e9624cb865  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/d458fc93-9725-4cf6-927b-66f80c71f01c  Claim in pharmacology — inconclusive  working
      ├─ used  claim/4ecb7119-969d-498c-a828-08d89fb25390  Claim in safety — inconclusive  working
      ├─ used  claim/e32894f6-96eb-4d5d-8a42-6d7e6a11e9a8  Claim in pharmacology — inconclusive  working
      ├─ used  claim/4056c22f-7baf-44bc-80a7-2769dc2f4dd4  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/b63e5424-7974-43a3-bd75-e3a4f7901654  Claim in neuroscience — inconclusive  working
      ├─ used  claim/dbd085a0-5a6a-468e-97fd-608dd314027f  Claim in neuroscience — inconclusive  working
      ├─ used  claim/c6cb1b26-860d-46df-bdfa-53b45260ab15  Claim in pharmacology — inconclusive  working
      ├─ used  claim/33b5fa22-fc74-48c3-b388-4ba64067aa95  Claim in pharmacology — inconclusive  working
      ├─ used  claim/e648c7ac-6a6a-4e50-8b4b-4c7ac64c5e14  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/e46f1fd9-9fc0-4431-b786-deeb7db592fd  Claim in pharmacology — inconclusive  working
      ├─ used  claim/8d8fd68d-4ab5-4f53-970d-cd048d2e6233  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/87df682b-74d7-49b6-8573-fab404e73123  Claim in pharmacology — inconclusive  working
      ├─ used  claim/7c0f4f5c-49fe-45a6-8ea2-c40023a20590  Claim in neuroscience — inconclusive  working
      ├─ used  claim/fa992791-c937-4dd3-8c55-4c4732290213  Claim in pharmacology — inconclusive  working
      ├─ used  claim/ac1d2ffd-0052-400a-9d53-7e154f4e17f4  Claim in pharmacology — inconclusive  working
      ├─ used  claim/c9e35203-0adc-4fdf-a388-9d5c90586f9c  Claim in pharmacology — inconclusive  working
      ├─ used  claim/669a6f0c-2aeb-4a19-b82f-8065c64e3e4a  Claim in neuroscience — inconclusive  working
      ├─ used  claim/4f1e860a-605e-4151-aa88-97daf5816b64  Claim in pharmacology — inconclusive  working
      ├─ used  claim/f7a7831f-98b5-4844-99f4-78c57c07e9a4  Claim in safety — inconclusive  working
      ├─ used  claim/337afeb9-6b31-4de8-9050-7169a2ee1a96  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/c6b5e60a-d72b-47fb-9916-8f43f4f13309  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/c2a0b0fb-1a11-4a7f-bbd0-d550b1637e10  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/4897ea39-8ff0-4202-93ac-a5b7284fef51  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/846c3f0f-ab12-4a5d-a8f6-6490be93b683  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/510b00a5-0afa-49e5-9caf-f93f8dc9bb06  Claim in neuroscience — inconclusive  working
      ├─ used  claim/0274b3f6-8f74-4850-aada-f7cfd63b6e92  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/6806182a-3400-4a8a-b4d0-ebec7c2b6600  Claim in neuroscience — inconclusive  working
      └─ used  claim/7a9c2029-78eb-4ebb-b46c-b0540d898f1e  Claim in comparative-pharmacology — inconclusive  working
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

3225 with DOI

20 strong · 8 moderate · 4 weak

Compilations

12026-05-11T11:15:59.053Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

23last ruled 2026-06-04

0 awaiting a ruling

Issued documents

52026-10-19T20:34:12.142Z

notice · info card · emergency

Searches

130 with no results

queries and counts on the build

Claims checked

7714 supported

14 supported · 63 not

Correspondence

0received

consent field ships in Phase 4

Edges

237

derivations recorded for this entity

Complete over 32 sources, 1 compilation, and 23 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/thcv/archive

2Build

one panel per compilation run

generation run 2026-05-11

60 min completedmodel pipeline-v5plan not recordedrun/954ed28e…

Selection

results seen907

selected by the model40

consumed as sources32

Verification

claims checked77

supported14

partially supported0

not supported0

inconclusive63

record
seen / partial
working

The model's own caveats

4 further caveats recorded as free text — readable on the working page

Reproduce

inputs: 32 source keys (listed under Sources)
plan: not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model: pipeline-v5
streams: none — agent transcripts are persisted from 2026-09 onward

13 searches — query, source, results, what was kept and why

13 searches for this run
#	source	query	seen	kept	rationale
1	PubChem	THCV	1	1	Primary chemical identity source
2	PubMed	THCV tetrahydrocannabivarin pharmacology receptor binding	14	14	All directly relevant to THCV pharmacology, mechanism, and therapeutic applications
3	OpenAlex	tetrahydrocannabivarin THCV cannabinoid receptor	846	3	High-citation landmark papers directly focused on THCV pharmacology
4	ClinicalTrials.gov	tetrahydrocannabivarin THCV	5	5	All relevant trials testing THCV in clinical populations
5	PubMed	tetrahydrocannabivarin neuroprotection Parkinson's disease	2	2	Both directly relevant to THCV neuroprotection in Parkinson's disease
6	PubMed	THCV tetrahydrocannabivarin obesity appetite diabetes metabolic	3	3	Relevant reviews and primary research on THCV metabolic effects
7	PubMed	THCV tetrahydrocannabivarin GWP42004 type 2 diabetes clinical trial	1	1	Key clinical trial paper - only published human RCT specifically on THCV
8	Crossref/DOI verification	Verify DOIs for key THCV papers	3	3	DOI verification for key clinical and pharmacology papers
9	PubMed	tetrahydrocannabivarin THCV insulin sensitivity mouse model obesity ameliorates glucose	1	1	Key preclinical metabolic study (Cawthorne lab) directly on THCV in obesity models
10	WebSearch	THCV tetrahydrocannabivarin DEA scheduling legal status USA UK controlled substance	10	2	Legal status not available via PubMed; web search required
11	WebSearch	THCV first isolation discovery 1970 Gill Jones cannabis history	10	2	Historical discovery data not available through PubMed
12	PubMed	THCV default mode network fMRI resting state functional connectivity brain imaging	1	1	First human fMRI study of THCV - important for subjective effects and brain pharmacology
13	WebSearch	THCV pharmacokinetics oral dose humans half-life Cmax tmax	10	2	Specific THCV PK data not available through PubMed search; web retrieval needed

77 claims by section — every cited sentence, checked against its source

pharmacology19 · 5 ok

Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
At low-to-moderate concentrations, THCV acts as a potent, competitive CB1 receptor neutral antagonist — blocking CB1 agonist signaling without constitutively suppressing baseline receptor activitysupported
antagonizes CB1 agonists in CB1-expressing tissues (tissue- and ligand-dependent) sj.bjp.0707442
This neutral antagonism distinguishes THCV from the CB1 inverse agonist rimonabant, which suppresses constitutive CB1 activity below baseline and was withdrawn from clinical use due to depression and suicidality.supported
not rimonabant-like bph.12944
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
At higher doses in vivo (above approximately 5 mg/kg i.p. in mice), THCV transitions to CB1 partial agonism, producing THC-like effects including hypothermia, catalepsy, and hypolocomotionsupported
at higher doses in vivo can act as CB1 agonist sj.bjp.0707442
At CB2 receptors, THCV consistently functions as a partial agonistsupported
potent CB2 partial agonist in vitro sj.bjp.0707442
At CB2 receptors, THCV consistently functions as a partial agonistsupported
CB2 partial agonist bph.12944
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →

safety13 · 2 ok

Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
McPartland et al. (2014) explicitly concluded that THCV is very unlikely to produce rimonabant-like CNS adverse effects.supported
not rimonabant-like bph.12944
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
McPartland et al. (2014) noted that because THCV is not a CB1 inverse agonist and does not potentiate endocannabinoid tone, the abuse liability profile is expected to differ substantially from THCsupported
THCV is a high-affinity CB1 receptor ligand and potent antagonist in vitro; not rimonabant-like bph.12944
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →

neuroscience8 · 1 ok

Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
This positions THCV within the theoretical framework of tonic vs. phasic endocannabinoid modulation: THCV may selectively blunt phasic endocannabinoid surges (such as those driving appetite in response to food cues) while preserving tonic signaling that maintains emotional homeostasis.supported
THCV is a high-affinity CB1 receptor ligand and potent antagonist in vitro; not rimonabant-like bph.12944
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →

clinical-evidence7 · 0 ok

Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →

summary7 · 2 ok

Claim in summary — inconclusiveinconclusiveworking →
This two-carbon truncation produces a qualitatively distinct pharmacological profile: THCV functions as a neutral CB1 receptor antagonist at low-to-moderate doses and transitions to CB1 partial agonism only at higher doses, a dose-dependent switch that is pharmacologically unusual within the cannabinoid class.supported
antagonizes CB1 agonists in CB1-expressing tissues (tissue- and ligand-dependent); at higher doses in vivo can act as CB1 agonist sj.bjp.0707442
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
The 13-week clinical trial reported no serious adverse events, and THCV's classification as a neutral antagonist — rather than an inverse agonist like rimonabant — predicts a lower risk of depressogenic side effectssupported
not rimonabant-like bph.12944

comparative-pharmacology6 · 1 ok

The structural difference between THCV (C3 side chain) and Δ9-THC (C5 side chain) produces a pharmacological inversion at CB1: THC is a partial agonist across all doses, while THCV antagonizes CB1 at low-to-moderate doses and transitions to partial agonism only at higher doses (above approximately 5 mg/kg i.p. in mice)supported
antagonizes CB1 agonists in CB1-expressing tissues (tissue- and ligand-dependent); at higher doses in vivo can act as CB1 agonist sj.bjp.0707442
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

receptor-pharmacology6 · 1 ok

Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
THCV, classified as a neutral antagonist, blocks agonist-induced signaling without suppressing constitutive activitysupported
THCV is a high-affinity CB1 receptor ligand and potent antagonist in vitro; not rimonabant-like bph.12944
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

chemistry4 · 1 ok

Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
This two-carbon truncation is the defining structural difference and underlies THCV's substantially divergent receptor pharmacologysupported
antagonizes CB1 agonists in CB1-expressing tissues; at higher doses in vivo can act as CB1 agonist; potent CB2 partial agonist in vitro sj.bjp.0707442

history4 · 0 ok

Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →

pharmacokinetic-detail2 · 0 ok

Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

effects-overview1 · 1 ok

Its closest functional comparator is not another cannabinoid but the withdrawn CB1 inverse agonist rimonabant — with the critical distinction that THCV's neutral antagonism avoids the depressogenic effects that ended rimonabant's clinical career.supported
not rimonabant-like; THCV is a high-affinity CB1 receptor ligand and potent antagonist in vitro; CB2 partial agonist bph.12944

3Sources

32 consumed · sorted by year · feeds = sections resting on it

Sources 1 to 30
year	source	tier	status	feeds
2025	THCV Legal Status by Country 2025: Canada, EU, Australiaurl:f455de69bfa40eb6	weak	consumed	cited only
2025	The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight managementMendoza S · AIMS Neurosciencedoi:10.3934/neuroscience.2025003	strong	consumed	cited only
2025	Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive StripsSmith GL · Cannabisdoi:10.26828/cannabis/2024/000206	moderate	consumed	2 sections
2024	Pharmacokinetics of Oral Cannabinoid Δ8-Tetrahydrocannabivarin and Its Main Metabolites in Healthy ParticipantsPeters EN et al. · Pharmaceuticalsurl:5a17861a26994f43	weak	consumed	cited only
2024	Tetrahydrocannabivarin — Wikipediaurl:fdd51976cdf438b4	weak	consumed	cited only
2024	THCV (Tetrahydrocannabivarin) — PubChem CID 93147PubChem · PubChem Compound Databasepmid:93147	moderate	consumed	1 section
2024	TRPV3 activation by different agonists accompanied by lipid dissociation from the vanilloid siteNadezhdin KD, Neuberger A, Khosrof LS, et al. · Science Advancesdoi:10.1126/sciadv.adn2453	strong	consumed	2 sections
2023	Hair Regrowth with Novel Hemp Extract: A Case SeriesSmith GL · International Journal of Trichologydoi:10.4103/ijt.ijt_34_22	weak	consumed	cited only
2023	Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling PathwayTortolani D, Di Meo C, Standoli S, et al. · International Journal of Molecular Sciencesdoi:10.3390/ijms24032721	strong	consumed	1 section
2022	Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human KeratinocytesDi Meo C, Tortolani D, Standoli S, et al. · International Journal of Molecular Sciencesdoi:10.3390/ijms23105430	strong	consumed	1 section
2021	Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic UsesWalsh KB, McKinney AE, Holmes AE · Frontiers in Pharmacologydoi:10.3389/fphar.2021.777804	moderate	consumed	1 section
2021	Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptorsRaïch I, Rivas-Santisteban R, Lillo A, et al. · Pharmacological Researchdoi:10.1016/j.phrs.2021.105970	strong	consumed	2 sections
2021	The biosynthesis of the cannabinoidsTahir MN, Shahbazi Raz F, Rondeau-Gagné S, Trant JF · Journal of Cannabis Researchdoi:10.1186/s42238-021-00062-4	strong	consumed	cited only
2020	A systematic review of minor phytocannabinoids with promising neuroprotective potential.Stone NL, Murphy AJ, England TJ, O'Sullivan SE · British Journal of Pharmacologydoi:10.1111/bph.15185	strong	consumed	2 sections
2020	Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson’s diseaseEspadas I, Keifman E, Palomo-Garo C, Burgaz S, García C, Fernández-Ruiz J, Moratalla R · Neurobiology of Diseasedoi:10.1016/j.nbd.2020.104892	moderate	consumed	2 sections
2020	Phytocannabinoids: Origins and BiosynthesisGülck T, Møller BL · Trends in Plant Sciencedoi:10.1016/j.tplants.2020.05.005	moderate	consumed	2 sections
2019	The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No Strain, No GainRusso EB · Frontiers in Plant Sciencedoi:10.3389/fpls.2018.01969	moderate	consumed	cited only
2016	Cannabis sativa: The Plant of the Thousand and One MoleculesAndre CM, Hausman JF, Guerriero G · Frontiers in Plant Sciencedoi:10.3389/fpls.2016.00019	moderate	consumed	cited only
2016	Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot StudyJadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, O'Sullivan SE, Tan GD · Diabetes Caredoi:10.2337/dc16-0650	strong	consumed	7 sections
2016	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophagesRomano B, Pagano E, Orlando P, Capasso R, Cascio MG, Pertwee R, Marzo VD, Izzo AA, Borrelli F · Pharmacological Researchdoi:10.1016/j.phrs.2016.07.045	strong	consumed	1 section
2015	The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy VolunteersRzepa E, Tudge L, McCabe C · The International Journal of Neuropsychopharmacologydoi:10.1093/ijnp/pyv092	strong	consumed	4 sections
2015	The phytocannabinoid, Δ9-tetrahydrocannabivarin, can act through 5-HT1A receptors to produce antipsychotic effectsCascio MG, Zamberletti E, Marini P, Parolaro D, Pertwee RG · British Journal of Pharmacologydoi:10.1111/bph.13000	strong	consumed	4 sections
2014	Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic reviewMcPartland JM, Duncan M, Di Marzo V, Pertwee RG · British Journal of Pharmacologydoi:10.1111/bph.12944	strong	consumed	6 sections
2012	Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptorsBátkai S, Mukhopadhyay P, Horváth B, et al. · British Journal of Pharmacologydoi:10.1111/j.1476-5381.2011.01410.x	strong	consumed	3 sections
2011	Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymesDe Petrocellis L, Ligresti A, Moriello AS, et al. · British Journal of Pharmacologydoi:10.1111/j.1476-5381.2010.01166.x	moderate	consumed	2 sections
2010	The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in miceBolognini D, Costa B, Maione S, Comelli F, Marini P, Di Marzo V, Parolaro D, Ross RA, Gaoun LA, Cascio MG, Pertwee RG · British Journal of Pharmacologydoi:10.1111/j.1476-5381.2010.00756.x	strong	consumed	2 sections
2010	Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult ratsHill AJ, Weston SE, Jones NA, Smith I, Bevan SA, Williamson EM, Stephens GJ, Williams CM, Whalley BJ · Epilepsiadoi:10.1111/j.1528-1167.2010.02523.x	strong	consumed	1 section
2009	Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted miceRiedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L · British Journal of Pharmacologypmid:19378378	strong	consumed	1 section
2008	Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranesDennis I, Whalley BJ, Stephens GJ · British Journal of Pharmacologydoi:10.1038/bjp.2008.190	strong	consumed	1 section
2007	The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarinPertwee RG · British Journal of Pharmacologydoi:10.1038/sj.bjp.0707442	strong	consumed	4 sections

Show all 32 sources — 2 more

Sources 31 to 32
year	source	tier	status	feeds
2007	The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivoPertwee RG, Thomas A, Stevenson LA, Ross RA, Varvel SA, Lichtman AH, Martin BR, Razdan RK · British Journal of Pharmacologypmid:17245367	strong	consumed	5 sections
2005	Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonistThomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG · British Journal of Pharmacologypmid:16205722	strong	consumed	5 sections

4Docket

one filing per activity — decisions, correspondence, reports

0012026-05-11revisionRevision 1
Initial LLM generation (v5 pipeline, wiki, prose phase)
psx:substance/thcv/version/1
0022026-06-04proposal21 value proposals approved together
one review action inferred from a shared reviewer and instant — the graph records one activity per proposal
21 items in this filing
- contraindication · psychiatric
- contraindication · hepatic
- contraindication · other
- contraindication · metabolic
- toxicity
- dependence · full
- withdrawal
- tolerance
- dose_tier · threshold
- dose_tier · light
- dose_tier · common
- dose_tier · strong
- dose_tier · heavy
- timeline · oral · onset
- timeline · oral · peak
- timeline · oral · afterglow
- dosage · oral
- duration · oral · onset
- duration · oral · peak
- duration · oral · total
psx:substance/thcv/proposal/contraindication/7fa22a6b-42f4-42ab-b06f-fd00e1223937
0032026-06-04publicationPublication — backfill
psx:substance/thcv/pub/afae88d3-595c-4917-81b6-039bec009d21

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
document	content hash	issued	from version	superseded
emergency	7386375eac1334714f070b93…	2026-10-19 20:34	Revision 1	current
info_card	4089953e287c8e9bf69c6d88…	2026-10-19 20:34	Revision 1	current
emergency	207cf682e28a91d88136b9a2…	2026-09-04 04:32	Revision 1	superseded2026-10-19
info_card	cbcce4ed045d621fbe56d8df…	2026-09-04 04:32	Revision 1	superseded2026-10-19
notice	6cc1eca3752c8ad4ae4d5c0c…	2026-09-04 04:32	Revision 1	current

THCV

6Node page

derived from · upstream

feeds · downstream

1Provenance card

2Build

generation run 2026-05-11

research→

draft→

audit→

verify→

simplify→

publish

Selection

Verification

The model's own caveats

Reproduce

3Sources

4Docket

5Issued documents

research

draft

audit

verify

simplify